Hypertension, Stable Chronic Kidney Disease
Conditions
Keywords
sympathetic activity, chronic kidney disease, atorvastatin, lipitor
Brief summary
Hypertensive chronic kidney disease (CKD) patients often have sympathetic hyperactivity which appears to contribute to the pathogenesis of hypertension and cardiovascular organ damage. Experimental studies and some clinical studies have shown that statin therapy can reduce central sympathetic activity. Blockade of the renin-angiotensin system (RAS), which is standard treatment for CKD, is known to lower sympathetic activity. The investigators hypothesize that adding a statin for 6 weeks to RAS blockade would further lower sympathetic activity in hypertensive stage 2-4 CKD patients. Methods: In ten stable CKD patients who are on chronic treatment with renin-angiotenis blockers, blood pressure and sympathetic activity (quantified by assessment of muscle sympathetic nerve activity, MSNA) will be assessed at baseline and 6 weeks after atorvastatin 20mg/day added. Ten other CKD patients will serve as time control and will be studied twice with an interval of 6 weeks without any change in medication, to quantify within subject reproducibility.
Detailed description
see above
Interventions
DRUGAtorvastatin
6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
Sponsors
UMC Utrecht
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 85 Years
Healthy volunteers
No
Inclusion criteria
* stable chronic kidney disease * Hypertension
Exclusion criteria
* renal replacement therapy * pregnancy * diabetes mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sympathetic activity | 4-6 weeks treatment |
Countries
Netherlands
Outcome results
None listed